{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:30:33Z","timestamp":1773246633984,"version":"3.50.1"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.arr.2021.101491","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T01:58:53Z","timestamp":1634867933000},"page":"101491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["The prognostic utility of CSF neurogranin in predicting future cognitive decline in the Alzheimer\u2019s disease continuum: A systematic review and meta-analysis with narrative synthesis"],"prefix":"10.1016","volume":"72","author":[{"given":"Si Qi","family":"Yoong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibek","family":"Gyanwali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue Qian","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi Vivien","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2021.101491_bib1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.arr.2021.101491_bib2","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/ene.14658","article-title":"Added value of cerebrospinal fluid multimarker analysis in diagnosis and progression of dementia","volume":"28","author":"\u00c1lvarez","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.arr.2021.101491_bib3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/alz.12068","article-title":"2020 Alzheimer\u2019s disease facts and figures","volume":"16","author":"Alzheimer\u2019s Association","year":"2020","journal-title":"Alzheimer\u2019s Dement."},{"key":"10.1016\/j.arr.2021.101491_bib4","unstructured":"Alzheimer\u2019s Disease Neuroimaging Initiative, 2017, Study design [WWW Document]. URL \u3008http:\/\/adni.loni.usc.edu\/study-design\/\u3009 (accessed 3 October 2021)."},{"key":"10.1016\/j.arr.2021.101491_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2020.117289","article-title":"Associations between cognitive and brain volume changes in cognitively normal older adults","volume":"223","author":"Armstrong","year":"2020","journal-title":"Neuroimage"},{"key":"10.1016\/j.arr.2021.101491_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5114\/fn.2019.85929","article-title":"Risk factors for Alzheimer\u2019s disease","volume":"57","author":"Armstrong","year":"2019","journal-title":"Folia Neuropathol."},{"key":"10.1016\/j.arr.2021.101491_bib7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3325\/cmj.2014.55.347","article-title":"Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease","volume":"55","author":"Babi\u0107","year":"2014","journal-title":"Croat. Med. J."},{"key":"10.1016\/j.arr.2021.101491_bib8","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1080\/13854046.2015.1119312","article-title":"How do scores on the ADAS-Cog, MMSE, and CDR-SOB correspond?","volume":"29","author":"Balsis","year":"2015","journal-title":"Clin. Neuropsychol."},{"key":"10.1016\/j.arr.2021.101491_bib9","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S0140-6736(15)00461-4","article-title":"Frontotemporal dementia","volume":"386","author":"Bang","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2021.101491_bib10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00002093-200210000-00001","article-title":"Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank","volume":"16","author":"Barker","year":"2002","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.arr.2021.101491_bib11","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.neuron.2019.01.056","article-title":"A quarter century of APOE and Alzheimer\u2019s disease: progress to date and the path forward","volume":"101","author":"Belloy","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2021.101491_bib12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/cc2955","article-title":"Statistics review 12: survival analysis","volume":"8","author":"Bewick","year":"2004","journal-title":"Crit. Care"},{"key":"10.1016\/j.arr.2021.101491_bib13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jalz.2014.02.004","article-title":"Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer\u2019s disease","volume":"11","author":"Blennow","year":"2015","journal-title":"Alzheimer\u2019s Dement."},{"key":"10.1016\/j.arr.2021.101491_bib14","doi-asserted-by":"crossref","first-page":"19024","DOI":"10.1038\/s41598-019-54204-z","article-title":"Predicting clinical decline and conversion to Alzheimer\u2019s disease or dementia using novel Elecsys A\u03b2(1\u201342), pTau and tTau CSF immunoassays","volume":"9","author":"Blennow","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2021.101491_bib15","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3233\/JAD-170773","article-title":"The past and the future of Alzheimer\u2019s disease fluid biomarkers","volume":"62","author":"Blennow","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"issue":"2","key":"10.1016\/j.arr.2021.101491_bib16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Research Synthesis Methods"},{"key":"10.1016\/j.arr.2021.101491_bib17","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jalz.2019.01.004","article-title":"Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer\u2019s disease spectrum","volume":"15","author":"Bos","year":"2019","journal-title":"Alzheimer\u2019s Dement."},{"key":"10.1016\/j.arr.2021.101491_bib18","series-title":"Memory Loss, Alzheimer\u2019s Disease, and Dementia: A Practical Guide for Clinicians","author":"Budson","year":"2017"},{"key":"10.1016\/j.arr.2021.101491_bib19","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1212\/WNL.0000000000004569","article-title":"Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers","volume":"89","author":"Casaletto","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101491_bib20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/joim.12495","article-title":"Alzheimer\u2019s disease with cerebrovascular disease: current status in the Asia\u2013Pacific region","volume":"280","author":"Chen","year":"2016","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.arr.2021.101491_bib21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1017\/S1355617711001524","article-title":"Specific measures of executive function predict cognitive decline in older adults","volume":"18","author":"Clark","year":"2012","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"10.1016\/j.arr.2021.101491_bib22","unstructured":"Cochrane GRADEing Methods Group, 2021, GRADEpro GDT [WWW Document]. URL \u3008https:\/\/methods.cochrane.org\/gradeing\/gradepro-gdt\u3009."},{"key":"10.1016\/j.arr.2021.101491_bib23","unstructured":"Cochrane Prognosis Methods, 2021a, Tools [WWW Document]. URL \u3008https:\/\/methods.cochrane.org\/prognosis\/tools\u3009."},{"key":"10.1016\/j.arr.2021.101491_bib24","unstructured":"Cochrane Prognosis Methods, 2021b, FAQ [WWW Document]. URL \u3008https:\/\/methods.cochrane.org\/prognosis\/faq\u3009."},{"key":"10.1016\/j.arr.2021.101491_bib25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1037\/h0026256","article-title":"Weighted kappa: nominal scale agreement provision for scaled disagreement or partial credit","volume":"70","author":"Cohen","year":"1968","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.arr.2021.101491_bib26","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s11682-012-9186-z","article-title":"Development and assessment of a composite score for memory in the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI)","volume":"6","author":"Crane","year":"2012","journal-title":"Brain Imaging Behav."},{"key":"10.1016\/j.arr.2021.101491_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40035-017-0093-5","article-title":"Role of BACE1 in Alzheimer\u2019s synaptic function","volume":"6","author":"Das","year":"2017","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.arr.2021.101491_bib28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000285520","article-title":"The vascular hypothesis of Alzheimer\u2019s disease: bench to bedside and beyond","volume":"7","author":"de la Torre","year":"2010","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.arr.2021.101491_bib29","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.jalz.2015.05.012","article-title":"C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer\u2019s disease","volume":"11","author":"De Vos","year":"2015","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.arr.2021.101491_bib30","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3233\/JAD-160227","article-title":"The cerebrospinal fluid neurogranin\/BACE1 ratio is a potential correlate of cognitive decline in Alzheimer\u2019s disease","volume":"53","author":"De Vos","year":"2016","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.arr.2021.101491_bib31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer\u2019s disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.arr.2021.101491_bib32","first-page":"47","article-title":"Alzheimer\u2019s disease: a healthcare burden of epidemic proportion","volume":"2","author":"Dharmarajan","year":"2009","journal-title":"Am. Heal. Drug Benefits"},{"key":"10.1016\/j.arr.2021.101491_bib33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1192\/bjp.bp.112.118307","article-title":"Late-life depression and risk of vascular dementia and Alzheimer\u2019s disease: Systematic review and meta-analysis of community-based cohort studies","volume":"202","author":"Diniz","year":"2013","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.arr.2021.101491_bib34","first-page":"21","article-title":"Neurogranin and VILIP-1 as molecular indicators of neurodegeneration in Alzheimer\u2019s disease: a systematic review and meta-analysis","author":"Dulewicz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2021.101491_bib35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrneurol.2017.96","article-title":"A clinicopathological approach to the diagnosis of dementia","volume":"13","author":"Elahi","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2021.101491_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.667899","article-title":"The effects of CSF neurogranin and APOE \u03b54 on cognition and neuropathology in mild cognitive impairment and Alzheimer\u2019s disease","volume":"13","author":"Fan","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2021.101491_bib37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fnagi.2014.00047","article-title":"Meta-review of CSF core biomarkers in Alzheimer\u2019s disease: the state-of-the-art after the new revised diagnostic criteria","volume":"6","author":"Ferreira","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2021.101491_bib38","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.trci.2019.11.002","article-title":"Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer\u2019s disease","volume":"5","author":"Galasko","year":"2019","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.arr.2021.101491_bib39","first-page":"3","article-title":"Elaborating on the assessment of the risk of bias in prognostic studies in pain rehabilitation using QUIPS\u2014aspects of interrater agreement","author":"Grooten","year":"2019","journal-title":"Diagn. Progn. Res."},{"issue":"1","key":"10.1016\/j.arr.2021.101491_bib40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archneur.61.1.59","article-title":"Mild Cognitive Impairment Can Be Distinguished from Alzheimer Disease and Normal Aging for Clinical Trials","volume":"61","author":"Grundman","year":"2004","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.arr.2021.101491_bib41","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.arr.2021.101491_bib42","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1161\/STROKEAHA.120.032571","article-title":"Blood-based cardiac biomarkers and the risk of cognitive decline, cerebrovascular disease, and clinical events","volume":"52","author":"Gyanwali","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.arr.2021.101491_bib43","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3233\/JAD-190540","article-title":"Mixed-location cerebral microbleeds: an imaging biomarker for cerebrovascular pathology in cognitive impairment and dementia in a memory clinic population","volume":"71","author":"Gyanwali","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.arr.2021.101491_bib44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","article-title":"Advantages and disadvantages of the use of the CSF Amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer\u2019s Disease","volume":"11","author":"Hansson","year":"2019","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10.1016\/j.arr.2021.101491_bib45","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.arr.2021.101491_bib46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2188\/jea.15.235","article-title":"Systematic evaluation and comparison of statistical tests for publication bias","volume":"15","author":"Hayashino","year":"2005","journal-title":"J. Epidemiol."},{"key":"10.1016\/j.arr.2021.101491_bib47","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.arr.2021.101491_bib48","doi-asserted-by":"crossref","first-page":"E887","DOI":"10.1212\/WNL.0000000000005057","article-title":"Neurogranin as a predictor of memory and executive function decline in MCI patients","volume":"90","author":"Headley","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101491_bib49","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuro.2017.03.006","article-title":"Risk factors associated with the onset and progression of Alzheimer\u2019s disease: a systematic review of the evidence","volume":"61","author":"Hersi","year":"2017","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.arr.2021.101491_bib50","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.arr.2021.101491_bib51","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br. Med. J."},{"key":"10.1016\/j.arr.2021.101491_bib52","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","article-title":"Ageing as a risk factor for neurodegenerative disease","volume":"15","author":"Hou","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2021.101491_bib53","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/2046-4053-2-71","article-title":"Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework","volume":"2","author":"Huguet","year":"2013","journal-title":"Syst. Rev."},{"key":"10.1016\/j.arr.2021.101491_bib54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1161\/HYPERTENSIONAHA.114.03040","article-title":"Hypertension and dementia","volume":"64","author":"Iadecola","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.arr.2021.101491_bib55","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.arr.2021.101491_bib56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/acn3.266","article-title":"Cerebrospinal fluid neurogranin and YKL \u201040 as biomarkers of Alzheimer\u2019s disease","volume":"3","author":"Janelidze","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.arr.2021.101491_bib57","unstructured":"Joanna Briggs Institute, 2020, 3.3.8 Sensitivity analysis in meta-analysis [WWW Document]. URL \u3008https:\/\/wiki.jbi.global\/display\/MANUAL\/3.3.8+Sensitivity+analysis+in+meta-analysis\u3009 (accessed 12 July 2020)."},{"key":"10.1016\/j.arr.2021.101491_bib58","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/jamaneurol.2015.1867","article-title":"Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease","volume":"72","author":"Kester","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2021.101491_bib59","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.trci.2018.10.003","article-title":"Cerebrospinal fluid neurogranin\/\u03b2-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer\u2019s disease","volume":"4","author":"Kirsebom","year":"2018","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.arr.2021.101491_bib60","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.mayocp.2014.06.019","article-title":"Mild cognitive impairment and mild dementia: a clinical perspective","volume":"89","author":"Knopman","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.arr.2021.101491_bib61","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.jalz.2014.10.009","article-title":"Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer\u2019s disease","volume":"11","author":"Kvartsberg","year":"2015","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.arr.2021.101491_bib62","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1212\/WNL.0000000000002576","article-title":"Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI","volume":"86","author":"Landau","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101491_bib63","article-title":"Molecular biomarkers of Alzheimer\u2019s disease: progress and prospects","volume":"11","author":"Lashley","year":"2018","journal-title":"DMM Dis. Model. Mech."},{"key":"10.1016\/j.arr.2021.101491_bib64","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3233\/JAD-140771","article-title":"Amyloid-\u03b2 42\/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer\u2019s disease: validation of two novel assays","volume":"43","author":"Lewczuk","year":"2014","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.arr.2021.101491_bib65","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.arr.2021.101491_bib66","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14737175.2016.1204234","article-title":"Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer\u2019s disease","volume":"17","author":"Lista","year":"2017","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.arr.2021.101491_bib67","first-page":"10","article-title":"Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer\u2019s disease and mild cognitive impairment","author":"Liu","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.arr.2021.101491_bib68","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.3390\/ijms20225536","article-title":"When does Alzheimer\u2032s disease really start? The role of biomarkers","volume":"20","author":"Lloret","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2021.101491_bib69","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.arcmed.2010.03.007","article-title":"The revitalized tau hypothesis on Alzheimer\u2019s disease","volume":"41","author":"Maccioni","year":"2010","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.arr.2021.101491_bib70","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.15252\/emmm.201606540","article-title":"Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer\u2019s disease","volume":"8","author":"Mattsson","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.arr.2021.101491_bib71","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s40520-019-01326-z","article-title":"A meta-analysis on CSF neurogranin levels for the diagnosis of Alzheimer\u2019s disease and mild cognitive impairment","volume":"32","author":"Mavroudis","year":"2020","journal-title":"Aging Clin. Exp. Res."},{"issue":"1","key":"10.1016\/j.arr.2021.101491_bib72","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk\u2010of\u2010bias VISualization (robvis): An R package and Shiny web app for visualizing risk\u2010of\u2010bias assessments.","volume":"12","author":"McGuinness","year":"2020","journal-title":"Research Synthesis Methods"},{"key":"10.1016\/j.arr.2021.101491_bib73","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.arr.2021.101491_bib74","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00401-018-1932-x","article-title":"Current state of Alzheimer\u2019s fluid biomarkers","volume":"136","author":"Molinuevo","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.arr.2021.101491_bib75","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s10433-012-0234-8","article-title":"Using the Folstein Mini Mental State Exam (MMSE) to explore methodological issues in cognitive aging research","volume":"9","author":"Monroe","year":"2012","journal-title":"Eur. J. Ageing"},{"key":"10.1016\/j.arr.2021.101491_bib76","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/ebmed-2016-110401","article-title":"New evidence pyramid","volume":"21","author":"Murad","year":"2016","journal-title":"BMJ Evid. -Based Med."},{"key":"10.1016\/j.arr.2021.101491_bib77","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s13760-017-0816-5","article-title":"Alzheimer\u2019s disease CSF biomarkers: clinical indications and rational use","volume":"117","author":"Niemantsverdriet","year":"2017","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.arr.2021.101491_bib78","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/0891988710363714","article-title":"The death knoll for the MMSE: Has it outlived its purpose?","volume":"23","author":"Nieuwenhuis-Mark","year":"2010","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"10.1016\/j.arr.2021.101491_bib79","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/S0140-6736(15)00463-8","article-title":"Vascular dementia","volume":"386","author":"O\u2019Brien","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2021.101491_bib80","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10.1016\/j.arr.2021.101491_bib81","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s12276-020-0418-9","article-title":"New fluid biomarkers tracking non-amyloid-\u03b2 and non-tau pathology in Alzheimer\u2019s disease","volume":"52","author":"Park","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.arr.2021.101491_bib82","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/joim.12190","article-title":"Mild cognitive impairment: a concept in evolution","volume":"275","author":"Petersen","year":"2014","journal-title":"J. Intern. Med."},{"issue":"136(3)","key":"10.1016\/j.arr.2021.101491_bib83","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00401-018-1851-x","article-title":"Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology","volume":"2018 136:3","author":"Portelius","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.arr.2021.101491_bib84","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1093\/brain\/awv267","article-title":"Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer\u2019s disease","volume":"138","author":"Portelius","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.arr.2021.101491_bib85","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.4, The Cochrane Collaboration, 2020."},{"key":"10.1016\/j.arr.2021.101491_bib86","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1523\/JNEUROSCI.10-12-03782.1990","article-title":"Neurogranin: Immunocytochemical localization of a brain-specific protein kinase C substrate","volume":"10","author":"Repress","year":"1990","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2021.101491_bib87","doi-asserted-by":"crossref","first-page":"k4597","DOI":"10.1136\/bmj.k4597","article-title":"A guide to systematic review and meta-analysis of prognostic factor studies","volume":"364","author":"Riley","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.arr.2021.101491_bib88","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00702-016-1597-3","article-title":"Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer\u2019s disease and in mild cognitive impairment due to AD","volume":"123","author":"Sanfilippo","year":"2016","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.arr.2021.101491_bib89","doi-asserted-by":"crossref","first-page":"e2845","DOI":"10.1212\/WNL.0000000000011029","article-title":"Brain amyloid \u03b2, cerebral small vessel disease, and cognition","volume":"95","author":"Saridin","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101491_bib90","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1212\/01.wnl.0000260698.46517.8f","article-title":"Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment","volume":"68","author":"Scheff","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101491_bib91","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006189","article-title":"Neuropathological alterations in Alzheimer disease","volume":"1","author":"Serrano-Pozo","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.arr.2021.101491_bib92","first-page":"8","article-title":"How to calculate sample size for observational and experimental nursing research studies?","volume":"10","author":"Sharma","year":"2020","journal-title":"Natl. J. Physiol. Pharm. Pharm."},{"key":"10.1016\/j.arr.2021.101491_bib93","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimer\u2019s Dement"},{"key":"10.1016\/j.arr.2021.101491_bib94","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.neuron.2014.05.004","article-title":"The intersection of amyloid beta and tau at synapses in Alzheimer\u2019s disease","volume":"82","author":"Spires-Jones","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2021.101491_bib95","first-page":"369","article-title":"The synaptic plasticity and memory hypothesis: encoding, storage and persistence","author":"Takeuchi","year":"2014","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"10.1016\/j.arr.2021.101491_bib96","doi-asserted-by":"crossref","DOI":"10.1177\/1177271920976367","article-title":"Biomarkers: our path towards a cure for Alzheimer disease","volume":"15","author":"Tarawneh","year":"2020","journal-title":"Biomark. Insights"},{"key":"10.1016\/j.arr.2021.101491_bib97","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jamaneurol.2016.0086","article-title":"Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease","volume":"73","author":"Tarawneh","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2021.101491_bib98","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/jpet.102.041616","article-title":"The cholinergic hypothesis of age and Alzheimer\u2019s disease-related cognitive deficits: recent challenges and their implications for novel drug development","volume":"306","author":"Terry","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.arr.2021.101491_bib99","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.2147\/IJN.S200490","article-title":"Alzheimer\u2019s disease: pathogenesis, diagnostics, and therapeutics","volume":"14","author":"Tiwari","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.arr.2021.101491_bib100","unstructured":"United Nations, 2019, Department of Economic and Social Affairs, Population Division. World Population Ageing 2019: Highlights."},{"key":"10.1016\/j.arr.2021.101491_bib101","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/WAD.0000000000000235","article-title":"Brain volumes and longitudinal cognitive change","volume":"32","author":"Vibha","year":"2018","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.arr.2021.101491_bib102","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(15)00462-6","article-title":"Lewy body dementias","volume":"386","author":"Walker","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2021.101491_bib103","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1159\/000354370","article-title":"Rate of conversion from prodromal Alzheimer\u2019s disease to Alzheimer\u2019s dementia: a systematic review of the literature","volume":"3","author":"Ward","year":"2013","journal-title":"Dement. Geriatr. Cogn. Dis. Extra"},{"key":"10.1016\/j.arr.2021.101491_bib104","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.theriogenology.2010.01.003","article-title":"Method agreement analysis: a review of correct methodology","volume":"73","author":"Watson","year":"2010","journal-title":"Theriogenology"},{"key":"10.1016\/j.arr.2021.101491_bib105","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1212\/WNL.0000000000002423","article-title":"Increased CSF neurogranin concentration is specific to Alzheimer disease","volume":"86","author":"Wellington","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101491_bib106","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1373\/clinchem.2017.283028","article-title":"Neurogranin as cerebrospinal fluid biomarker for Alzheimer disease: An assay comparison study","volume":"64","author":"Willemse","year":"2018","journal-title":"Clin. Chem."},{"key":"10.1016\/j.arr.2021.101491_bib107","first-page":"S171","article-title":"Economic burden of Alzheimer disease and managed care considerations","volume":"26","author":"Wong","year":"2020","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.arr.2021.101491_bib108","unstructured":"World Health Organisation, 2020, Dementia [WWW Document]. URL \u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia#:~:text=Social and economic impact&text=In 2015%2C the total global,%25 in high-income countries\u3009 (accessed 12 July 2020)."},{"key":"10.1016\/j.arr.2021.101491_bib109","first-page":"12","article-title":"Neurogranin: a potential biomarker of neurological and mental diseases","author":"Xiang","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2021.101491_bib110","doi-asserted-by":"crossref","first-page":"9365","DOI":"10.18632\/aging.103211","article-title":"Association of cerebrospinal fluid neurogranin levels with cognition and neurodegeneration in Alzheimer\u2019s disease","volume":"12","author":"Xue","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.arr.2021.101491_bib111","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/biomedicines7040097","article-title":"Reasons for failed trials of disease-modifying treatments for Alzheimer disease and their contribution in recent research","volume":"7","author":"Yiannopoulou","year":"2019","journal-title":"Biomedicines"},{"key":"10.1016\/j.arr.2021.101491_bib112","doi-asserted-by":"crossref","DOI":"10.1177\/1179573520907397","article-title":"Current and future treatments in Alzheimer disease: an update","volume":"12","author":"Yiannopoulou","year":"2020","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.arr.2021.101491_bib113","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1037\/neu0000141","article-title":"Differing effects of education on cognitive decline in diverse elders with low versus high educational attainment","volume":"29","author":"Zahodne","year":"2015","journal-title":"Neuropsychology"},{"key":"10.1016\/j.arr.2021.101491_bib114","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.3233\/JAD-201608","article-title":"Differential impact of education on cognitive performance in neurological patients with progressive cognitive decline","volume":"80","author":"Zamarian","year":"2021","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.arr.2021.101491_bib115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/alzrt24","article-title":"Inflammation in Alzheimer\u2019s disease: relevance to pathogenesis and therapy","volume":"2","author":"Zotova","year":"2010","journal-title":"Alzheimer\u2019s Res. Ther."}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163721002385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163721002385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:58:37Z","timestamp":1761591517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163721002385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":115,"alternative-id":["S1568163721002385"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2021.101491","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prognostic utility of CSF neurogranin in predicting future cognitive decline in the Alzheimer\u2019s disease continuum: A systematic review and meta-analysis with narrative synthesis","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2021.101491","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101491"}}